Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement
Sahai SK, Balonov K, Bentov N, Bierle DMM, Browning LM, Cummings KC, Dougan BM, Maxwell M, Merli GJ, Oprea AD, Sweitzer B, Mauck KF, Urman RD. Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clinic Proceedings 2022, 97: 1734-1751. PMID: 36058586, DOI: 10.1016/j.mayocp.2022.03.039.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAngiotensin Receptor AntagonistsAnti-Arrhythmia AgentsAntihypertensive AgentsCalcium Channel BlockersHumansHypertensionPotassiumQuality ImprovementSodiumSodium Chloride Symporter InhibitorsConceptsCardiovascular medicationsPerioperative assessmentAntiarrhythmic agentsReceptor antagonistAngiotensin receptor neprilysin inhibitorQuality Improvement (SPAQI) Consensus StatementAngiotensin II receptor blockersClass I antiarrhythmic agentsClass III antiarrhythmic agentII receptor blockersClasses of medicationsEndothelin receptor antagonistsPotassium-sparing diureticsCalcium channel blockersΒ-adrenoceptor blockersAdrenergic receptor antagonistPhosphodiesterase-5 inhibitorsEvidence-based recommendationsSodium channel blockersPotassium channel openersSympatholytic medicationsReceptor blockersPerioperative managementHeart failureLoop diuretics